The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumoursin vitro

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

(2013) C. M. Cannon et al.   Veterinary and Comparative Oncology

Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

(2012) Yongshun Chen et al.   CANCER SCIENCE

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

(2012) Alice Dewdney et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer

(2012) L. Mitchell et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks

(2011) M. Wang et al.   CANCER RESEARCH

Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications

(2011) Eugenia García-Fernández et al.   HISTOPATHOLOGY

Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs

(2011) Patricia C. Schultheiss et al.   JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study

(2011) C. Robat et al.   Veterinary and Comparative Oncology

Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours

(2011) C. London et al.   Veterinary and Comparative Oncology

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

(2010) Xiaojing Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models

(2010) J. J. Tentler et al.   CLINICAL CANCER RESEARCH

Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma

(2010) Heini Lassus et al.   GYNECOLOGIC ONCOLOGY

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

(2010) Ingrid M.E. Desar et al.   INTERNATIONAL JOURNAL OF CANCER

Dependence of Cell Survival on Iododeoxyuridine Concentration in 35-keV Photon-Activated Auger Electron Radiotherapy

(2010) Joseph P. Dugas et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Outcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases (1997–2007)

(2010) Carrie Tupper Hume et al.   JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION

Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors

(2010) M. F. YANCEY et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours

(2010) K. M. Rassnick et al.   Veterinary and Comparative Oncology

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines

(2010) Yoshinori Takeuchi et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

Canine Subcutaneous Mast Cell Tumors

(2010) J. J. Thompson et al.   VETERINARY PATHOLOGY

Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision

(2009) C. A. London et al.   CLINICAL CANCER RESEARCH

Aurora kinases as prognostic biomarkers in ovarian carcinoma

(2009) Marta Mendiola et al.   HUMAN PATHOLOGY

Analysis of Aurora B kinase in non-Hodgkin lymphoma

(2009) Takayuki Ikezoe et al.   LABORATORY INVESTIGATION

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases

(2009) Maureen Cooper et al.   Veterinary and Comparative Oncology

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

(2008) Y. Nadler et al.   CLINICAL CANCER RESEARCH

Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours*

(2008) G. A. Maglennon et al.   Veterinary and Comparative Oncology

Aurora kinases as targets for cancer therapy

(2007) Giannis Mountzios et al.   CANCER TREATMENT REVIEWS